Public Employees Retirement System of Ohio Buys New Stake in Aurinia Pharmaceuticals Inc $AUPH

Public Employees Retirement System of Ohio bought a new stake in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 33,329 shares of the biotechnology company’s stock, valued at approximately $282,000.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Acropolis Investment Management LLC acquired a new position in shares of Aurinia Pharmaceuticals during the 2nd quarter valued at $242,000. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Aurinia Pharmaceuticals by 20.8% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 12,989 shares of the biotechnology company’s stock valued at $110,000 after acquiring an additional 2,238 shares in the last quarter. City Center Advisors LLC acquired a new position in shares of Aurinia Pharmaceuticals during the 2nd quarter valued at $222,000. Voya Investment Management LLC lifted its holdings in Aurinia Pharmaceuticals by 14.8% in the 1st quarter. Voya Investment Management LLC now owns 69,687 shares of the biotechnology company’s stock worth $560,000 after buying an additional 8,999 shares in the last quarter. Finally, Strs Ohio acquired a new position in Aurinia Pharmaceuticals in the 1st quarter worth $636,000. Institutional investors and hedge funds own 36.83% of the company’s stock.

Insider Buying and Selling at Aurinia Pharmaceuticals

In other news, Director Kevin Tang purchased 200,000 shares of the company’s stock in a transaction on Tuesday, August 5th. The shares were bought at an average price of $11.68 per share, for a total transaction of $2,336,000.00. Following the completion of the purchase, the director owned 11,329,500 shares of the company’s stock, valued at $132,328,560. This trade represents a 1.80% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders have bought 1,300,000 shares of company stock worth $13,590,000. 12.20% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

AUPH has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a report on Saturday, September 27th. Royal Bank Of Canada boosted their price objective on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the stock an “outperform” rating in a report on Friday, August 1st. Finally, HC Wainwright reiterated a “buy” rating and issued a $17.00 price objective on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, Aurinia Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $13.00.

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ:AUPH opened at $11.32 on Tuesday. The company has a quick ratio of 4.63, a current ratio of 5.23 and a debt-to-equity ratio of 0.18. Aurinia Pharmaceuticals Inc has a fifty-two week low of $6.55 and a fifty-two week high of $13.54. The firm has a 50-day simple moving average of $11.89 and a 200 day simple moving average of $9.44. The company has a market cap of $1.49 billion, a PE ratio of 26.33 and a beta of 1.25.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.01). Aurinia Pharmaceuticals had a net margin of 23.31% and a return on equity of 20.06%. The business had revenue of $70.01 million for the quarter, compared to the consensus estimate of $64.27 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current year.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.